• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

特应性皮炎中CD45ROCLA⁺H4R⁺ T细胞中白细胞介素-31的产生

Production of IL-31 in CD45ROCLAH4R T Cells in Atopic Dermatitis.

作者信息

Bang Chul Hwan, Song Ji Young, Song Yu Mee, Lee Ji Hyun, Park Young Min, Lee Jun Young

机构信息

Department of Dermatology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul 06591, Korea.

Program of Immunology & Microbiology, Department of Biomedicine & Health Science, Graduate School, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul 06591, Korea.

出版信息

J Clin Med. 2021 May 4;10(9):1976. doi: 10.3390/jcm10091976.

DOI:10.3390/jcm10091976
PMID:34064490
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8124489/
Abstract

IL-31 is involved in pruritus in atopic dermatitis (AD) and the pathogenesis of AD. However, the mechanism of IL-31 production is not fully understood. We sought to investigate the association between CD45ROCLAH4R T cells and IL-31 production. Immunofluorescence studies were performed retrospectively on punch-biopsy specimens from five people with AD and three healthy controls. In addition, blood samples were collected prospectively from eight patients with AD and eight healthy controls for sorting CD45ROCLAH4R T cells. There was no overlap of patients between the biopsy group and the blood sampling group. Sorted cells were stimulated with 4-methylhistamine (4MH), and the level of IL-31 was measured by an enzyme-linked immunosorbent assay. Immunofluorescence showed co-localization of H4R and IL-31 in lesional AD skin but not in normal skin of healthy controls. The proportion of CLAH4R T cells among CD3CD45RO lymphocytes was 18.3 ± 6.2% in patients with AD and 11.2 ± 7.6% in healthy controls. In the AD group, production of IL-31 by CD45ROCLAH4R T cells increased from 32.4 ± 13.3 pg/mL to 47.5 ± 18.7 pg/mL by 4MH stimulation after 24 h ( < 0.001). However, in the control group, production of IL-31 was 20.1 ± 10.6 pg/mL without and 22.1 ± 9.3 pg/mL with 4MH stimulation ( > 0.05). According to our study, CD45ROCLAH4R T cells are an important source of IL-31 in AD, and may be a target for treatment of IL-31-induced pruritus.

摘要

白细胞介素-31(IL-31)参与特应性皮炎(AD)的瘙痒及AD的发病机制。然而,IL-31产生的机制尚未完全明确。我们试图研究CD45ROCLA⁺H4R⁺ T细胞与IL-31产生之间的关联。对来自5例AD患者和3名健康对照的打孔活检标本进行回顾性免疫荧光研究。此外,前瞻性收集8例AD患者和8名健康对照的血样,用于分选CD45ROCLA⁺H4R⁺ T细胞。活检组和血样采集组之间没有患者重叠。分选后的细胞用4-甲基组胺(4MH)刺激,通过酶联免疫吸附测定法测量IL-31水平。免疫荧光显示H4R和IL-31在AD皮损皮肤中共定位,但在健康对照的正常皮肤中未共定位。AD患者中CD3⁺CD45RO⁺淋巴细胞中CLA⁺H4R⁺ T细胞的比例为18.3±6.2%,健康对照中为11.2±7.6%。在AD组中,CD45ROCLA⁺H4R⁺ T细胞产生的IL-31在24小时经4MH刺激后从32.4±13.3 pg/mL增加到47.5±18.7 pg/mL(P<0.001)。然而,在对照组中,未刺激时IL-31产生量为20.1±10.6 pg/mL,4MH刺激后为22.1±9.3 pg/mL(P>0.05)。根据我们的研究,CD45ROCLA⁺H4R⁺ T细胞是AD中IL-31的重要来源,可能是治疗IL-31诱导瘙痒的靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61d3/8124489/2ab5c53bb84c/jcm-10-01976-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61d3/8124489/939ef9b6a846/jcm-10-01976-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61d3/8124489/8f2547ed6cc1/jcm-10-01976-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61d3/8124489/520a8429ddd5/jcm-10-01976-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61d3/8124489/2ab5c53bb84c/jcm-10-01976-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61d3/8124489/939ef9b6a846/jcm-10-01976-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61d3/8124489/8f2547ed6cc1/jcm-10-01976-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61d3/8124489/520a8429ddd5/jcm-10-01976-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61d3/8124489/2ab5c53bb84c/jcm-10-01976-g004.jpg

相似文献

1
Production of IL-31 in CD45ROCLAH4R T Cells in Atopic Dermatitis.特应性皮炎中CD45ROCLA⁺H4R⁺ T细胞中白细胞介素-31的产生
J Clin Med. 2021 May 4;10(9):1976. doi: 10.3390/jcm10091976.
2
IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis.白细胞介素-31与特应性皮炎患者中皮肤淋巴细胞抗原阳性的皮肤归巢T细胞相关。
J Allergy Clin Immunol. 2006 Feb;117(2):418-25. doi: 10.1016/j.jaci.2005.10.046.
3
Increased type 2 cytokine expression by both CD4+ CD45RO+ T cells and CD8+ CD45RO+ T cells in blood circulation is associated with high serum IgE but not with atopic dermatitis.血液循环中CD4+ CD45RO+ T细胞和CD8+ CD45RO+ T细胞中2型细胞因子表达增加与高血清IgE相关,但与特应性皮炎无关。
J Invest Dermatol. 1998 Dec;111(6):1079-84. doi: 10.1046/j.1523-1747.1998.00454.x.
4
Circulating allergen-reactive T cells from patients with atopic dermatitis and allergic contact dermatitis express the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen.来自特应性皮炎和过敏性接触性皮炎患者的循环变应原反应性T细胞表达皮肤选择性归巢受体,即皮肤淋巴细胞相关抗原。
J Exp Med. 1995 May 1;181(5):1935-40. doi: 10.1084/jem.181.5.1935.
5
Skin-homing, CLA+ memory T cells are activated in atopic dermatitis and regulate IgE by an IL-13-dominated cytokine pattern: IgG4 counter-regulation by CLA- memory T cells.皮肤归巢的CLA+记忆T细胞在特应性皮炎中被激活,并通过以白细胞介素-13为主导的细胞因子模式调节IgE:CLA-记忆T细胞对IgG4的反向调节。
J Immunol. 1997 Nov 1;159(9):4611-9.
6
Skin homing (cutaneous lymphocyte-associated antigen-positive) CD8+ T cells respond to superantigen and contribute to eosinophilia and IgE production in atopic dermatitis.皮肤归巢(皮肤淋巴细胞相关抗原阳性)CD8 + T细胞对超抗原产生反应,并在特应性皮炎中导致嗜酸性粒细胞增多和IgE产生。
J Immunol. 1999 Jul 1;163(1):466-75.
7
Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population.严重特应性皮炎的特征是循环中 TH2/TC2 和 TH22/TC22 细胞而非 TH17/TC17 细胞的选择性扩增,这些细胞存在于皮肤归巢 T 细胞群中。
J Allergy Clin Immunol. 2015 Jul;136(1):104-115.e7. doi: 10.1016/j.jaci.2015.01.020. Epub 2015 Mar 3.
8
Naïve CD4+ T cells from patients with atopic dermatitis show an aberrant maturation towards IL-4-producing skin-homing CLA+ cells.特应性皮炎患者的初始CD4 + T细胞向产生白细胞介素-4的皮肤归巢CLA +细胞呈现异常成熟。
Exp Dermatol. 2003 Oct;12(5):555-62. doi: 10.1034/j.1600-0625.2003.00096.x.
9
Cytokine production, activation marker, and skin homing receptor in children with atopic dermatitis and bronchial asthma.特应性皮炎和支气管哮喘患儿的细胞因子产生、活化标志物及皮肤归巢受体
Pediatr Allergy Immunol. 2006 May;17(3):166-74. doi: 10.1111/j.1399-3038.2006.00390.x.
10
Calcitonin gene-related peptide modulates interleukin-13 in circulating cutaneous lymphocyte-associated antigen-positive T cells in patients with atopic dermatitis.降钙素基因相关肽调节特应性皮炎患者循环中皮肤淋巴细胞相关抗原阳性 T 细胞中的白细胞介素-13。
Br J Dermatol. 2009 Sep;161(3):547-53. doi: 10.1111/j.1365-2133.2009.09318.x. Epub 2009 Jun 29.

引用本文的文献

1
Race science without racists: how bigoted paradigms persist in allergy research.无种族主义者的种族科学:在过敏研究中如何坚持偏见范式。
Front Public Health. 2024 Jul 10;12:1351732. doi: 10.3389/fpubh.2024.1351732. eCollection 2024.
2
Blockage of the IL-31 Pathway as a Potential Target Therapy for Atopic Dermatitis.阻断白细胞介素-31通路作为特应性皮炎的潜在靶向治疗方法
Pharmaceutics. 2023 Feb 8;15(2):577. doi: 10.3390/pharmaceutics15020577.

本文引用的文献

1
New treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines.针对白细胞介素 4/13 细胞因子的新型特应性皮炎治疗方法。
Ann Allergy Asthma Immunol. 2020 Jan;124(1):28-35. doi: 10.1016/j.anai.2019.10.005. Epub 2019 Oct 14.
2
The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study.口服 Janus 激酶/脾酪氨酸激酶抑制剂 ASN002 在中重度特应性皮炎患者中显示出疗效,并改善相关的全身炎症:一项随机双盲安慰剂对照研究的结果。
Br J Dermatol. 2019 Oct;181(4):733-742. doi: 10.1111/bjd.17932. Epub 2019 May 6.
3
GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis.
GBR 830,一种抗 OX40 药物,改善了特应性皮炎患者的皮肤基因特征和临床评分。
J Allergy Clin Immunol. 2019 Aug;144(2):482-493.e7. doi: 10.1016/j.jaci.2018.11.053. Epub 2019 Feb 6.
4
Atopic dermatitis endotypes and implications for targeted therapeutics.特应性皮炎的表型和对靶向治疗的影响。
J Allergy Clin Immunol. 2019 Jan;143(1):1-11. doi: 10.1016/j.jaci.2018.10.032.
5
Efficacy and safety of the histamine H receptor antagonist ZPL-3893787 in patients with atopic dermatitis.组胺 H 受体拮抗剂 ZPL-3893787 治疗特应性皮炎患者的疗效和安全性。
J Allergy Clin Immunol. 2019 May;143(5):1830-1837.e4. doi: 10.1016/j.jaci.2018.07.047. Epub 2018 Nov 9.
6
Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study.巴瑞替尼治疗中重度特应性皮炎成人患者的疗效:一项 2 期平行、双盲、随机安慰剂对照、多剂量研究。
J Am Acad Dermatol. 2019 Apr;80(4):913-921.e9. doi: 10.1016/j.jaad.2018.01.018. Epub 2018 Feb 2.
7
IL-31: A new key player in dermatology and beyond.白细胞介素-31:皮肤科及其他领域的新关键角色。
J Allergy Clin Immunol. 2018 Mar;141(3):858-866. doi: 10.1016/j.jaci.2017.10.045. Epub 2018 Feb 1.
8
Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial. fezakinumab(一种 IL-22 单克隆抗体)在常规治疗未能充分控制的中重度特应性皮炎成人患者中的疗效和安全性:一项随机、双盲、2a 期试验。
J Am Acad Dermatol. 2018 May;78(5):872-881.e6. doi: 10.1016/j.jaad.2018.01.016. Epub 2018 Jan 17.
9
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.度普利尤单抗联合外用皮质类固醇治疗中重度特应性皮炎的长期管理(LIBERTY AD CHRONOS):一项为期 1 年、随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2017 Jun 10;389(10086):2287-2303. doi: 10.1016/S0140-6736(17)31191-1. Epub 2017 May 4.
10
Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis.抗白细胞介素-31 受体 A 抗体治疗特应性皮炎。
N Engl J Med. 2017 Mar 2;376(9):826-835. doi: 10.1056/NEJMoa1606490.